Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Finding of Duomeisu in Neoadjuvant Breast Cancer
NCT03017404Phase 1Completed
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- May 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Duomeisu in breast cancer (4 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Maximum Tolerated Dose. Started May 2015; status: completed.
02
Drugs
Duomeisu
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03017404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03017404.